Zawel Leigh 4
4 · Cullinan Oncology, Inc. · Filed Aug 11, 2021
Insider Transaction Report
Form 4
Zawel Leigh
See Remarks
Transactions
- Sale
Common Stock
2021-08-10$26.50/sh−1,906$50,509→ 126,650 total - Sale
Common Stock
2021-08-10$27.34/sh−3,191$87,242→ 123,459 total - Sale
Common Stock
2021-08-10$28.49/sh−1,817$51,766→ 121,642 total - Sale
Common Stock
2021-08-09$26.52/sh−19,504$517,246→ 130,256 total - Sale
Common Stock
2021-08-09$27.11/sh−1,700$46,087→ 128,556 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.